OrthoLogic/J&J's DePuy AcroMed
This article was originally published in The Gray Sheet
Johnson & Johnson DePuy AcroMed subsidiary gains exclusive worldwide rights to sell OrthoLogic's SpinaLogic non-invasive lumbar stimulation device, which is used as an adjunctive treatment after lumbar spinal fusion to increase the probability of successful fusion. The ten-year agreement that began Aug. 18 is expected to advance SpinaLogic's presence in the domestic and international spinal market
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.